Relationship of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3

Growth Hormone and IGF Research

Volumn 21, Issue 3, 2011, Pages 146-154

  Safarinejad, Mohammad Reza ^a   Shafiei, Nayyer ^a   Safarinejad, Shiva ^a  

^a Private Practice of Urology and Andrology   (Iran)

Author keywords

Gene; Genetic; Insulin like growth factor binding protein 3; Polymorphism; Prostatic hyperplasia; Prostatic neoplasms

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ADVANCED CANCER; AGE; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER STAGING; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; DNA ISOLATION; DNA POLYMORPHISM; GENE AMPLIFICATION; GENE FREQUENCY; GENOTYPE; GLEASON SCORE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AGED; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 79958210009     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2011.03.008     Document Type: Article

References (64)

1. Hsing A.W., Tsao L., Devesa S.S. International trends and patterns of prostate cancer incidence and mortality. Int. J. Cancer 2000, 85:60-67.
2. Bosland M.C. Sex steroids and prostate carcinogenesis: integrated, multifactorial working hypothesis. Ann. N.Y. Acad. Sci. 2006, 1089:168-176.
3. Janssen J.A., Lamberts S.W. The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible?. Eur. J. Endocrinol. 2002, 146:467-477.
4. Bach L.A., Headey S.J., Norton R.S. IGF-binding proteins-the pieces are falling into place. Trends Endocrinol. Metab. 2005, 16:228-234.
5. Dunn S.E., Hardman R.A., Kari F.W., Barrett J.C. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL 100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res. 1997, 57:2687-2693.
6. Parrizas M., LeRoith D. Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology 1997, 138:1355-1358.
7. Jones J.I., Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 1995, 16:3-34.
8. Perks C.M., Holly J.M. IGF binding proteins (IGFBPs) and regulation of breast cancer biology. J. Mammary Gland Biol. Neoplasia 2008, 13:455-469.
9. Vesely D., Astl J., Latuvka P., Matucha P., Betka J. Serum levels of IGFI, HGF, TGFβ1, bFGF and VEGF in thyroid gland tumors. Physiol. Res. 2004, 53:83-89.
10. Gucev Z.S., Oh Y., Kelley K.M., Rosenfeld R.G. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res. 1996, 56:1545-1550.
11. Buckbinder L., Talbott R., Velasco-Miguel S., Takenaka I., Faha B., Seizinger B.R., Kley N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995, 377:646-649.
12. Hong J., Zhang G., Dong F., Rechler M.M. Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells. J. Biol. Chem. 2002, 277:10489-10497.
13. Shahjee H., Bhattacharyya N., Zappala G., Wiench M., Prakash S., Rechler M.M. An N-terminal fragment of insulin-like growth factor binding protein-3 (IGFBP-3) induces apoptosis in human prostate cancer cells in an IGF-independent manner. Growth Horm. IGF Res. 2008, 18:188-197.
14. Hanafusa T., Yumoto Y., Nouso K., Nakatsukasa H., Onishi T., Fujikawa T., Taniyama M., Nakamura S., Uemura M., Takuma Y., Yumoto E., Higashi T., Tsuji T. Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett. 2002, 176:149-158.
15. Chang Y.S., Kong G., Sun S., Liu D., El-Naggar A.K., Khuri F.R., Hong W.K., Lee H.Y. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin. Cancer Res. 2002, 8:3796-3802.
16. Baricevic I., Masnikosa R., Lagundzin D., Golubovic V., Nedic O. Alterations of insulin-like growth factor binding protein 3 (IGFBP-3) glycosylation in patients with breast tumours. Clin. Biochem. 2010, 43:725-731.
17. Wang L., Habuchi T., Tsuchiya N., Mitsumori K., Ohyama C., Sato K., Kinoshita H., Kamoto T., Nakamura A., Ogawa O., Kato T. Insulin-like growth factor-binding protein-3 gene 2202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res. 2003, 63:4407-4411.
18. Ramachandran S., Liu P., Young A.N., Yin-Goen Q., Lim S.D., Laycock N., Amin M.B., Carney J.K., Marshall F.F., Petros J.A., Moreno C.S. Loss of HOXC6 expression induces apoptosis in prostate cancer cells. Oncogene 2005, 24:188-198.
19. Grimberg A., Cohen P. Role of insulin like growth factors and their binding proteins in growth control and carcinogenesis. J. Cell. Physiol. 2000, 183:1-9.
20. Harrela M., Koistinen H., Kaprio J., Lehtovirta M., Tuomilehto J., Eriksson J., Toivanen L., Koskenvuo M., Leinonen P., Koistinen R., Seppala M. Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3. J. Clin. Invest. 1996, 98:2612-2615.
21. Kao P.C., Matheny A.P.J., Lang C.A. Insulin-like growth factor-I comparisons in healthy twin children. J. Clin. Endocrinol. Metab. 1994, 78:310-312.
22. Ehrenborg E., Larsson C., Stern I., Janson M., Powell D.R., Luthman H. Contiguous localization of the genes encoding human insulin-like growth factor binding proteins 1 (IGBP1) and 3 (IGBP3) on chromosome 7. Genomics 1992, 12:497-502.
23. Deal C., Ma J., Wilkin F., Paquette J., Rozen F., Ge B., Hudson T., Stampfer M., Pollak M. Novel promoter polymorphism in insulin-like growth factor binding protein-3: correlation with serum levels and interaction with known regulators. J. Clin. Endocrinol. Metab. 2001, 86:1274-1280.
24. Jernström H., Deal C., Wilkin F., Chu W., Tao Y., Majeed N., Hudson T., Narod S.A., Pollak M. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol. Biomarkers Prev. 2001, 10:377-384.
25. Massoner P., Haag P., Seifarth C., Jurgeit A., Rogatsch H., Doppler W., Bartsch G., Klocker H. Insulin-like growth factor binding protein-3 (IGFBP-3) in the prostate and in prostate cancer: local production, distribution and secretion pattern indicate a role in stromal-epithelial interaction. Prostate 2008, 68:1165-1178.
26. Silha J.V., Sheppard P.C., Mishra S., Gui Y., Schwartz J., Dodd J.G., Murphy L.J. Insulin-like growth factor (IGF) binding protein-3 attenuates prostate tumor growth by IGF-dependent and IGF-independent mechanisms. Endocrinology 2006, 147:2112-2121.
27. Chen C., Freeman R., Voigt L.F., Fitzpatrick A., Plymate S.R., Weiss N.S. Prostate cancer risk in relation to selected genetic polymorphisms in insulin-like growth factor-I, insulin-like growth factor binding protein-3, and insulin-like growth factor-I receptor. Cancer Epidemiol. Biomarkers Prev. 2006, 15:2461-2466.
28. Severi G., Morris H.A., MacInnis R.J., English D.R., Tilley W.D., Hopper J.L., Boyle P., Giles G.G. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2006, 15:1137-1141.
29. Platz E.A., Pollak M.N., Leitzmann M.F., Stampfer M.J., Willett W.C., Giovannucci E. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control 2005, 16:255-262.
30. Kehinde E.O., Akanji A.O., Mojiminiyi O.A., Bashir A.A., Daar A.S., Varghese R. Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men. Prostate Cancer Prostatic Dis. 2005, 8:84-90.
31. Li H., Bubley G.J., Balk S.P., Gaziano J.M., Pollak M., Stampfer M.J., Ma J. Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. Prostate 2007, 67:1354-1361.
32. Allen N.E., Key T.J., Appleby P.N., Travis R.C., Roddam A.W., Rinaldi S., Egevad L., Rohrmann S., Linseisen J., Pischon T., Boeing H., Johnsen N.F., Tjønneland A., Grønbaek H., Overvad K., Kiemeney L., Bueno-de-Mesquita H.B., Bingham S., Khaw K.T., Tumino R., Berrino F., Mattiello A., Sacerdote C., Palli D., Quirós J.R., Ardanaz E., Navarro C., Larrañaga N., Gonzalez C., Sanchez M.J., Trichopoulou A., Travezea C., Trichopoulos D., Jenab M., Ferrari P., Riboli E., Kaaks R. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol. Biomarkers Prev. 2007, 16:1121-1127.
33. Hong S.K., Han B.K., Jeong J.S., Jeong S.J., Moon K.H., Byun S.S., Lee S.E. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men. Asian J. Androl. 2008, 10:207-213.
34. Johansson M., McKay J.D., Rinaldi S., Wiklund F., Adami H.O., Grönberg H., Kaaks R., Stattin P. Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival. Prostate 2009, 69:1281-1291.
35. Rowlands M.A., Gunnell D., Harris R., Vatten L.J., Holly J.M., Martin R.M. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int. J. Cancer 2009, 124:2416-2429.
36. Roddam A.W., Allen N.E., Appleby P., Key T.J., Ferrucci L., Carter H.B., Metter E.J., Chen C., Weiss N.S., Fitzpatrick A., Hsing A.W., Lacey J.V., Helzlsouer K., Rinaldi S., Riboli E., Kaaks R., Janssen J.A., Wildhagen M.F., Schröder F.H., Platz E.A., Pollak M., Giovannucci E., Schaefer C., Quesenberry C.P., Vogelman J.H., Severi G., English D.R., Giles G.G., Stattin P., Hallmans G., Johansson M., Chan J.M., Gann P., Oliver S.E., Holly J.M., Donovan J., Meyer F., Bairati I., Galan P. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann. Intern. Med. 2008, 149:461-471.
37. Cancer International Union Against Urological tumours. TNM Classification of Malignant Tumours 1997, 170-173. Wiley-Liss, New York. Ed. 5. L.H. Sobin, C. Wittekind (Eds.).
38. Safarinejad M.R. Insulin-like growth factor binding protein-3 (IGFBP-3) gene variants are associated with renal cell carcinoma. BJU 2010, [Epub ahead of print].
39. Jernstrom H., Deal C., Wilkin F., Chu W., Tao Y., Majeed N., Hudson T., Narod S.A., Pollak M. Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin like growth factor-binding protein-3 in healthy premenopausal women. Cancer Epidemiol. Biomarkers Prev. 2001, 10:377-384.
40. Schernhammer E.S., Hankinson S.E., Hunter D.J., Blouin M.J., Pollak M.N. Polymorphic variation at the 2202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int. J. Cancer 2003, 107:60-64.
41. Slipicevic A., Øy G.F., Askildt I.C., Holth A., Hellesylt E., Flørenes V.A., Davidson B. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions. Hum. Pathol. 2009, 40:527-537.
42. Nam R.K., Trachtenberg J., Jewett M.A., Toi A., Evans A., Emami M., Narod S.A., Pollak M. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 2005, 14:1270-1273.
43. Chen C., Lewis S.K., Voigt L., Fitzpatrick A., Plymate S.R., Weiss N.S. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer 2005, 103:76-84.
44. Janssen J.A., Wildhagen M.F., Ito K., Blijenberg B.G., Van Schaik R.H., Roobol M.J., Pols H.A., Lamberts S.W., Schröder F.H. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval. J. Clin. Endocrinol. Metab. 2004, 89:4391-4396.
45. Li L., Yu H., Schumacher F., Casey G., Witte J.S. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control 2003, 14:721-726.
46. Chokkalingam A.P., Pollak M., Fillmore C.M., Gao Y.T., Stanczyk F.Z., Deng J., Sesterhenn I.A., Mostofi F.K., Fears T.R., Madigan M.P., Ziegler R.G., Fraumeni J.F., Hsing A.W. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol. Biomarkers Prev. 2001, 10:421-427.
47. Neuhouser M.L., Schenk J., Song Y.J., Tangen C.M., Goodman P.J., Pollak M., Penson D.F., Thompson I.M., Kristal A.R. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate 2008, 68:1477-1486.
48. Miyata Y., Sakai H., Hayashi T., Kanetake H. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer. Prostate 2003, 54:125-132.
49. Giovannucci E. Insulin like growth factor I and binding protein 3 and risk of cancer. Hormone Res. 1999, 51((suppl):3):34-41.
50. Pollak M. Insulin like growth factor physiology and cancer risk. Eur. J. Cancer 2000, 36:1224-1228.
51. Liu B., Lee K.W., Anzo M., Zhang B., Zi X., Tao Y., Shiry L., Pollak M., Lin S., Cohen P. Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene 2007, 26:1811-1819.
52. Meyer F., Galan P., Douville P., Bairati I., Kegle P., Bertrais S., Czernichow S., Hercberg S. A prospective study of the insulin-like growth factor axis in relation with prostate cancer in the SU.VI.MAX trial. Cancer Epidemiol. Biomarkers Prev. 2005, 14:2269-2272.
53. Aksoy Y., Aksoy H., Bakan E., Atmaca A.F., Akçay F. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia. Urol. Int. 2004, 72:62-65.
54. Lu L., Katsaros D., Wiley A., Rigault de la Longrais I.A., Risch H.A., Puopolo M., Yu H. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer. Clin. Cancer Res. 2006, 12:1208-1214.
55. Latif Z., McMillan D.C., Wallace A.M., Sattar N., Mir K., Jones G., Underwood M.A. The relationship of circulating insulin-like growth factor 1, its binding protein-3, prostate-specific antigen and C-reactive protein with disease stage in prostate cancer. BJU Int. 2002, 89:396-399.
56. Baserga R. The IGF-I receptor in cancer research. Exp. Cell Res. 1999, 253:1-6.
57. Liu B., Lee K.W., Li H., Ma L., Lin G.L., Chandraratna R.A., Cohen P. Combination therapy of insulin-like growth factor binding protein-3 and retinoid X receptor ligands synergize on prostate cancer cell apoptosis in vitro and in vivo. Clin. Cancer Res. 2005, 11:4851-4856.
58. Bhattacharyya N., Pechhold K., Shahjee H., Zappala G., Elbi C., Raaka B., Wiench M., Hong J., Rechler M.M. Nonsecreted insulin-like growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human prostate cancer cells by IGF-independent mechanisms without being concentrated in the nucleus. J. Biol. Chem. 2006, 281:24588-24601.
59. Vijayababu M.R., Arunkumar A., Kanagaraj P., Arunakaran J. Effects of quercetin on insulin-like growth factors (IGFs) and their binding protein-3 (IGFBP-3) secretion and induction of apoptosis in human prostate cancer cells. J. Carcinog. 2006, 5:10.
60. Devi G.R., Sprenger C.C., Plymate S.R., Rosenfeld R.G. Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo. Prostate 2002, 51:141-152.
61. Khandwala H.M., McCutcheon I.E., Flyvbjerg A., Friend K.E. The effects of insulin like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev. 2000, 21:215-244.
62. Rajaram S., Baylink D.J., Mohan S. Insulin like growth factor binding proteins in serum and other biological fluids: regulation and functions. Endocr. Rev. 1997, 18:801-831.
63. Baxter R.C. Signalling pathways involved in antiproliferative effects of IGFBP-3: a review. Mol. Pathol. 2001, 54:145-148.
64. Yu H., Spitz M.R., Mistry J., Gu J., Hong W.K., Wu X. Plasma levels of insulin like growth factor-1 and lung cancer risk: a case control analysis. J. Natl. Cancer Inst. 1999, 91:151-156.